RXST · RxSight
AI read · Bad for RXST
The AI's read
The sales decline came as competition reduced demand for LAL procedures. RxSight is trying to improve adoption with a larger sales team, and its Alcon work has passed a 120-day milestone. Those steps could help later, but savings from its restructuring are expected in 2027 or later, and the company gave no formal forecast for 2026. The current sales drop carries more weight than these plans.